Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients

doi:10.2147/OTT.S257991

HFCAS OpenIR

	Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients
	Wei, Weitian 1,2,3; Li, Xingliang 4; Song, Mengmeng 5; Wang, Changchun 1,2,3
	2020
发表期刊	ONCOTARGETS AND THERAPY
ISSN	1178-6930
通讯作者	Wang, Changchun(ccw7878@163.com)
摘要	Objective: To investigate the genetic mutations in both tumor and marginal tissues in patients with non-small cell lung cancer (NSCLC), and to evaluate the potential prognostic value in patients with margins gene positive. Methods: Next-generation sequencing (NGS) technique was used to detect genetic mutation in tumor and marginal tissues of the bronchus in 88 patients with NSCLC. Correlation of genetic mutations with pathology, lymph node metastasis, disease-free survival and overall survival was analyzed. Results: Of the 88 patients, 83 cases (94.3%) had gene mutations in the tumor samples and 12 cases (13.6%) had genetic alterations in their margins. Most of the gene mutations detected were cancer drivers. Six common driver genes between tumor and marginal tissues were identified, including EGFR, TP53, CDKN2A, CTNNB1, BRAF, and NF1. Kaplan-Meier analysis revealed that the median disease-free survival (DFS) was significantly shorter in patients with detectable gene mutations in marginal tissues compared with patients without mutations in margins (30.7 versus 24.4 months, log-rank chi(2) = 4.78, P =0.029). Consistently, a shorter median OS was observed in patients harboring gene mutations in margins compared with patients with no mutations in margins (49.1 versus 32.2 months, log-rank chi(2) = 3.669, P =0.055). Conclusion: These findings identify the presence of oncogenic alterations in microscopically negative margins in NSCLC patients associated with elevated risk of relapse and shorter survival time. Thus, examination of microscopically negative margins by NGS represents a valuable approach to predict the clinical outcome of NSCLC patients.
关键词	lung cancer gene mutation surgical margin next-generation sequencing
DOI	10.2147/OTT.S257991
关键词[WOS]	POST-RECURRENCE SURVIVAL ; BRONCHIAL MARGINS
收录类别	SCI
语种	英语
资助项目	Zhejiang Provincial Natural Science - Mathematical Medicine Association Joint Fund[LSY19H160001] ; Medical and Health of Zhejiang Province Scientific Research Project[2013KYA031]
项目资助者	Zhejiang Provincial Natural Science - Mathematical Medicine Association Joint Fund ; Medical and Health of Zhejiang Province Scientific Research Project
WOS研究方向	Biotechnology & Applied Microbiology ; Oncology
WOS类目	Biotechnology & Applied Microbiology ; Oncology
WOS记录号	WOS:000575933700001
出版者	DOVE MEDICAL PRESS LTD
引用统计	被引频次：2[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/104459
专题	中国科学院合肥物质科学研究院
通讯作者	Wang, Changchun
作者单位	1.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou 310022, Peoples R China 2.Univ Chinese Acad Sci, Dept Thorac Oncol Surg, Canc Hosp, Hangzhou 310022, Peoples R China 3.Zhejiang Canc Hosp, Dept Thorac Oncol Surg, Hangzhou 310022, Peoples R China 4.Zhejiang Rongjun Hosp, Dept Thorac Dis, Diag & Treatment Ctr, Jiaxing 314000, Zhejiang, Peoples R China 5.Geneplus Beijing Inst, Beijing 102206, Peoples R China
推荐引用方式 GB/T 7714	Wei, Weitian,Li, Xingliang,Song, Mengmeng,et al. Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients[J]. ONCOTARGETS AND THERAPY,2020,13.
APA	Wei, Weitian,Li, Xingliang,Song, Mengmeng,&Wang, Changchun.(2020).Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients.ONCOTARGETS AND THERAPY,13.
MLA	Wei, Weitian,et al."Molecular Analysis of Oncogenic Mutations in Resected Margins by Next-Generation Sequencing Predicts Relapse in Non-Small Cell Lung Cancer Patients".ONCOTARGETS AND THERAPY 13(2020).